26
2020-08
Interview of Zaiqi Wang – Chairman & CEO, InxMed by PharmaBoardroom
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.
24
2020-06
SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,
17
2020-03
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
07
2020-01
Shanghai, China – InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company
20
2019-12
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the Company has obtained IND (Investigational New Drug) clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor, from China National Medical Products Administration (NMPA) to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer. Previously IN10018 has opened IND in the United States in August 2019.
12
2019-10
InxMed Announces Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib
Shanghai, China – InxMed (Shanghai) Co., Ltd., (“InxMed” or “Company”) today announced that the company has entered into a clinical collaboration with Roche (F. Hoffmann-La Roche Ltd.,) to evaluate IN10018, a proprietary focal adhesion kinase (FAK) inhibitor in combination with Roche’s Cobimetinib, an inhibitor of mitogen-activated protein kinase (MEK).
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE